Understanding how certain cancer cells become more likely to spread
Integrators of Metastatic Potential
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-10599845
This study is working on new ways to tailor cancer treatments by finding out which patients are more likely to have their cancer spread, so those at higher risk can get stronger therapies while others can avoid tough side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10599845 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new tools to personalize cancer treatment based on the risk of metastasis, which is when cancer spreads to other parts of the body. By identifying specific signaling molecules that indicate a cancer cell's potential to metastasize, the study aims to create biosensors that can detect these signals in living cancer cells. Patients identified as high-risk for metastasis would receive more aggressive, targeted therapies, while those at lower risk could avoid unnecessary side effects from harsh treatments. This approach seeks to improve treatment outcomes and reduce toxicity for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with solid tumors, particularly those at risk for metastatic breast cancer.
Not a fit: Patients with early-stage cancers that are not expected to metastasize may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments that minimize side effects for patients.
How similar studies have performed: Other research has shown promise in using molecular imaging and biosensors to understand cancer metastasis, indicating that this approach could be a significant advancement in cancer treatment.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GHOSH, PRADIPTA — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: GHOSH, PRADIPTA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, anticancer agent